DBV Technologies (DBVT) Operating Margin (2020 - 2026)
DBV Technologies (DBVT) posted Operating Margin of 7228.57% for Q2 2026, down 35.82% sequentially from 5322.22% in Q1 2026, and down 448857.0% YoY from N/an in Q2 2025.
Powered by 
Analysis
DBV Technologies (DBVT) Operating Margin (2020 - 2026) Analysis & Trends
DBV Technologies has reported Operating Margin for 7 years, with the latest figure at 7228.57% in Q2 2026.
- Quarterly Operating Margin fell 448857.0% year-over-year to 7228.57% in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 3543.1% (down 44317.0% YoY) and the FY2025 annual result came in at 2609.23%, up 16670.0% from the prior year.
- Operating Margin slipped to 7228.57% in Q2 2026 per DBVT's latest filing, from 5322.22% in the prior quarter.
- Over five years, Operating Margin peaked at 2915.41% in Q4 2022 and troughed at 7228.57% in Q2 2026.
- A 5-year average of 2333.67% and a median of 1793.89% in 2024 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2022 and 2026: Operating Margin jumped 337507 bps in 2022, then sank 448857 bps in 2026.
- Over 5 years, Operating Margin stood at 2915.41% in 2022, then slumped by 105 bps to 134.31% in 2023, then tumbled by 3072 bps to 4260.89% in 2024, then tumbled by 64 bps to 6984.65% in 2025, then dropped by 3 bps to 7228.57% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 7228.57%, 5322.22%, and 6984.65% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 19.75% |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -0.36% |
| 10 | DBV Technologies | 5.86 Bn | 5.68 Bn | - | -7,228.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -7,228.57% |
| Mar 31, 2026 | -5,322.22% |
| Dec 31, 2025 | -6,984.65% |
| Sep 30, 2025 | -1,235.65% |
| Jun 30, 2025 | -2,740.00% |
| Mar 31, 2025 | -3,325.00% |
| Dec 31, 2024 | -4,260.89% |
| Sep 30, 2024 | -2,829.10% |
| Jun 30, 2024 | -2,914.90% |
| Mar 31, 2024 | -2,029.71% |
| Dec 31, 2023 | -134.31% |
| Sep 30, 2023 | -770.24% |
| Jun 30, 2023 | -1,095.98% |
| Mar 31, 2023 | -964.68% |
| Dec 31, 2022 | 2,915.41% |
| Sep 30, 2022 | -868.85% |
| Jun 30, 2022 | -1,558.08% |
| Mar 31, 2022 | -658.72% |
| Dec 31, 2021 | -459.65% |
| Sep 30, 2021 | -1,841.87% |